Who is sponsoring NCT03295422?

NCT03295422 is sponsored by Sequoia Hospital.

What drugs are being tested in NCT03295422?

Interventions in NCT03295422: RF ablation PVI alone, RF ablation PVI plus LPAW.

What condition does NCT03295422 study?

NCT03295422 studies Chronic Atrial Fibrillation, Persistent Atrial Fibrillation.

Is NCT03295422 still recruiting?

NCT03295422 is currently status unknown. Last updated 19 November 2020.

Last reviewed 2020-11-19 · How we verify

NCT03295422

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Two Pulmonary Vein Ablation Techniques for Persistent AF

Status unknown NA Last updated 19 November 2020

What this trial tests

NA trial testing RF ablation PVI alone in Chronic Atrial Fibrillation in 100 participants. Status unknown.

Timeline

25 August 2017

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Sequoia Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	25 August 2017
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across United States

Drugs / interventions tested

RF ablation PVI alone
RF ablation PVI plus LPAW

Conditions studied

Chronic Atrial Fibrillation — all drugs for Chronic Atrial Fibrillation →
Persistent Atrial Fibrillation — all drugs for Persistent Atrial Fibrillation →

Sponsor

Sequoia Hospital

Who can join

18 and older, any sex, with Chronic Atrial Fibrillation or Persistent Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigator initiated, randomized controlled trial of two radiofrequency (RF)ablation protocols currently performed in the electrophysiology lab, but have not been studied prospectively to identify which, if either technique, is superior for individuals with persistent atrial fibrillation (AF). Two-hundred subjects will be consecutively enrolled and randomized to either pulmonary vein isolation only or pulmonary vein isolation plus posterior left atrial wall isolation

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recurrent atrial fibrillation after pulmonary vein isolation: Box it or not?
Barnett AS, Bahnson TD. · · 2021 · cited 1× · PMID 34667965 · DOI 10.1016/j.hroo.2021.09.002

Verify or expand the search:

Other recruiting trials for Chronic Atrial Fibrillation

Currently open trials in the same condition.

NCT05393180 — CONVERGE Post-Approval Study (PAS) · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03295422 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sequoia Hospital
Last refreshed: 19 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03295422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing